Edition:
United Kingdom

LivaNova PLC (LIVN.OQ)

LIVN.OQ on NASDAQ Stock Exchange Global Select Market

82.62USD
8 Dec 2017
Change (% chg)

$-1.30 (-1.55%)
Prev Close
$83.92
Open
$83.99
Day's High
$84.12
Day's Low
$82.62
Volume
144,188
Avg. Vol
142,597
52-wk High
$88.42
52-wk Low
$44.67

Select another date:

Tue, Dec 5 2017

BRIEF-Livanova To Acquire Imthera Medical

* LIVANOVA PLC SAYS ENTERED INTO AN AGREEMENT TO ACQUIRE REMAINING OUTSTANDING INTERESTS IN IMTHERA MEDICAL, INC.

BRIEF-Microport Scientific's unit buys CRM business from Livanova

* ‍Unit buys CRM business for initial consideration of US$190 million​ from Livanova PLC Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

BRIEF-LivaNova Plc reports ‍Q3 diluted earnings per share were $0.57​

* LivaNova Plc - ‍Q3 2017 diluted earnings per share were $0.57​

BRIEF-Livanova receives FDA approval for Vagus Nerve Stimulation Therapy system​

* Livanova receives FDA approvals for SenTiva device and next-generation VNS therapy programming system for treatment of epilepsy

BRIEF-Livanova and Microport announce approval of Rega pacemakers by China FDA

* Livanova and Microport announce the approval of Rega pacemakers by the China Food and Drug Administration

BRIEF-Livanova announces U.S. Launch of Optiflow Arterial Cannulae Family

* Says ‍received FDA 510(k) clearance for U.S. Market launch of its Optiflow Arterial Cannulae Family​ Source text for Eikon: Further company coverage:

BRIEF-LivaNova ‍expects to achieve revenue growth in mid-single-digits in near term and high-single-digits in long term​

* LivaNova Plc - ‍Expects to achieve revenue growth in mid-single-digits in near term and high-single-digits in long term​

BRIEF-Livanova ‍Q2 adjusted EPS $1.01​

* Q2 earnings per share view $0.82, revenue view $315.6 million -- Thomson Reuters I/B/E/S

BRIEF-VNS Therapy receives FDA approval for expanded MRI Labeling

* VNS Therapy receives FDA approval for expanded mri labeling

Select another date: